SREBF2 and cancer: Interestingly, upon treatment with non-cytotoxic ISO1 or C0, there was no significant difference in the levels of neither the cleaved SREBP2 nor mLDLR at both timepoints and across multiple cancer cell lines tested (Fig. 5b–e), suggesting that activation of the cholesterol pathway was unique to the cytotoxic effects of S2Ls.